Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
02:43pm, Wednesday, 14'th Feb 2024
It is entirely fair to state that weight loss treatments have massive transformational power. US FDA approval of weight loss medicines could help shrink millions of waistlines.
1 Potential Catalyst That Could Light a Fire Under Novo Nordisk's Stock This Year
08:30am, Wednesday, 14'th Feb 2024
Top weight-loss treatment Wegovy generated 400% revenue growth for Novo Nordisk in 2023. The drug can, however, cost patients without insurance coverage more than $16,000 per year.
Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?
02:59am, Wednesday, 14'th Feb 2024
Amgen is the latest big pharma to join the gold rush to treat obesity. Its candidate is distinct from the medicines by Eli Lilly and Novo Nordisk.
EDEN: Denmark Exposure With A Lot Of Novo Nordisk
02:02pm, Tuesday, 13'th Feb 2024
iShares MSCI Denmark ETF has benefited from weight loss drugs and has a weighting of 23% in the ETF. The EDEN ETF provides exposure to a wide range of Danish companies and is ideal for those looking f
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
05:50am, Tuesday, 13'th Feb 2024
Eli Lilly and Novo Nordisk stocks have soared, thanks largely to their weight-loss drugs. However, analysts think that another big pharma stock will perform much better over the near term.
Why Novo Nordisk (NVO) is a Top Stock for the Long-Term
10:30am, Monday, 12'th Feb 2024
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Novo Nordisk's Magic Run Continues Even With Increasing Competition
09:15am, Monday, 12'th Feb 2024
Novo Nordisk is the developer of blockbuster drugs Ozempic, Rybelsus, and Wegovy. The popularity of these treatments is fueling impressive growth and a bright outlook.
Novo Nordisk's controlling shareholder plans to invest up to $7 bln a year by 2030 - FT
12:50am, Monday, 12'th Feb 2024
Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , plans to invest up to $7 billion annually by 2030, the Financial Times reported on Monday.
Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?
12:25pm, Sunday, 11'th Feb 2024
Novo Nordisk is selling Wegovy faster than it can be made. It's scaling up production as well as acquiring more capacity.
Don't Worry About Novo Nordisk's Premium Stock Price. It's Still a Buy.
10:15am, Sunday, 11'th Feb 2024
Sales from Ozempic, Rybelsus, and Wegovy are increasing at unprecedented rates. Investors have continued to buy up stock in Novo Nordisk as its magic run continues.
Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited
09:53am, Saturday, 10'th Feb 2024
Novo Nordisk just acquired Catalent, a subcontractor for the company's drug production. Per the deal, Novo Nordisk will take over three of Catalent's production plants.
Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
08:00am, Saturday, 10'th Feb 2024
Novo Nordisk and Eli Lilly have given positive supply updates, aiming to reassure investors that they can continue to capitalize on the success of their drugs.
Is It Really Just the Magnificent 7 Propping Up This Market?
02:36pm, Friday, 09'th Feb 2024
The choir has been preaching that these seven stocks are holding up an overall weak market.
Catalent Q2 sales inch past estimates amid takeover by Novo Holdings
09:25am, Friday, 09'th Feb 2024
Catalent reported second-quarter revenue slightly above Wall Street estimates on Friday, days after the contract drug manufacturer agreed to a $16.5-billion acquisition offer from Novo Nordisk's paren
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
04:56pm, Thursday, 08'th Feb 2024
Demand is surging for weight-loss treatments that are being rolled out by major pharmaceutical companies. Investors are still trying to assess the full market opportunity and competitive landscape.
